ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-SIRPa Monoclonal Antibody BI 770371

Its studies are mostly in Squamous Cell Carcinoma of Head and Neck · Fatty Liver, led by Boehringer Ingelheim.

Drug pageAnti-SIRPa Monoclonal Antibody BI 770371: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Nov 4, 20244 company-led studies, 3 open or runningNext primary completion: Aug 31, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim43 open or runningphase 2since Nov 4, 2024Sep 19, 2021Aug 31, 2027phase 1 · NCT06806852

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 19, 2021First study: phase 1 study in CarcinomaFirst studyNCT05068102 · 14 enrolled · Netherlands
  2. Apr 8, 2022Phase 1 study in Solid TumorsNCT05327946 · 42 enrolled · United States, Canada, Japan
  3. Nov 4, 2024Phase 2 study in Compensated Liver CirrhosisNCT06675929 · 28 enrolled · United States
  4. Jan 28, 2025Phase 1 study in Squamous Cell Carcinoma of Head and NeckNCT06806852 · 91 enrolled · United States, Australia, Brazil and more

Ahead

  1. Aug 31, 2027Primary completion: phase 1 study in Squamous Cell Carcinoma of Head and NeckNCT06806852

TargetBeta

SIRPA →read by rule
“An immunoglobulin G1 (IgG1) monoclonal antibody targeting human signal-regulatory protein alpha (SIRPa; CD172a), ”NCIt, by rule

Other programs on SIRPA

ProgramCompanyFurthest phaseStudies
Anti-SIRPa Monoclonal Antibody DS-1103ruleDaiichi Sankyophase 22
Anti-SIRPalpha Monoclonal Antibody BYON4228rulebyondis-b-vphase 12

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06806852Squamous Cell Carcinoma of Head and Neck · United States, Australia, Brazil and more1Active, not recruitingAug 31, 202791
NCT06675929Compensated Liver Cirrhosis · United States2CompletedJan 13, 202628
NCT05327946Solid Tumors · United States, Canada, Japan1Active, not recruitingJul 16, 202442
NCT05068102Carcinoma · Netherlands1Active, not recruitingJan 22, 202614

How it is read

Names in the registry

  • “BI 770371”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.